Details of the Drug Combination

General Information of Drug Combination (ID: DCHRZGZ)

Drug Combination Name

Lenalidomide Terameprocol

Indication

Disease Entry	Status	REF
Adenocarcinoma	Investigative	[1]

Component Drugs

Lenalidomide DM6Q7U4

Terameprocol DMC3P45

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: HCC-2998

Zero Interaction Potency (ZIP) Score: 0.23

Bliss Independence Score: 6.61

Loewe Additivity Score: 6.26

LHighest Single Agent (HSA) Score: 5.78

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Lenalidomide

Disease Entry	ICD 11	Status	REF
Adult T-cell leukemia/lymphoma	N.A.	Approved	[2]
Advanced cancer	2A00-2F9Z	Approved	[2]
Complex regional pain syndrome type 1	N.A.	Approved	[2]
Hepatosplenic T-cell lymphoma	N.A.	Approved	[2]
Large granular lymphocytic leukemia	2A90.1	Approved	[2]
Leukemia	N.A.	Approved	[2]
MALT lymphoma	N.A.	Approved	[2]
Multiple myeloma	2A83	Approved	[3]
Nodal marginal zone lymphoma	2A85.0	Approved	[2]
Pain	MG30-MG3Z	Approved	[2]
Plasma cell myeloma	2A83.1	Approved	[2]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified	N.A.	Approved	[2]
Prolymphocytic leukaemia	2A82.1	Approved	[2]
Recurrent adult burkitt lymphoma	2A85.6	Approved	[2]
Small intestine lymphoma	N.A.	Approved	[2]
Splenic marginal zone lymphoma	N.A.	Approved	[2]
Testicular lymphoma	N.A.	Approved	[2]
Urinary bladder neoplasm	N.A.	Approved	[2]
Waldenstrom macroglobulinemia	2A85.4	Approved	[2]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 3	[4]
Colon cancer	2B90.Z	Investigative	[2]

Lenalidomide Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Tumor necrosis factor (TNF)	TTF8CQI	TNFA_HUMAN	Inhibitor	[6]
------------------------------------------------------------------------------------

Lenalidomide Interacts with 1 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[7]
------------------------------------------------------------------------------------

Lenalidomide Interacts with 5 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A)	OT2D9DOV	TNR1A_HUMAN	Decreases Expression	[8]
Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B)	OTDS2EAR	TNR1B_HUMAN	Decreases Expression	[8]
Interleukin-6 receptor subunit beta (IL6ST)	OT1N9C70	IL6RB_HUMAN	Decreases Expression	[8]
DNA damage-binding protein 1 (DDB1)	OTTR2L3Z	DDB1_HUMAN	Affects Binding	[9]
Sal-like protein 4 (SALL4)	OTC08PR5	SALL4_HUMAN	Affects Binding	[10]
------------------------------------------------------------------------------------

Indication(s) of Terameprocol

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[5]

Terameprocol Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Transcription factor Sp1 (SP1)	TTZEP6S	SP1_HUMAN	Modulator	[5]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Clear cell renal cell carcinoma	DC5EXVJ	CAKI-1	Investigative	[11]
Plasma cell myeloma	DCL8AGF	RPMI-8226	Investigative	[11]
Carcinoma	DCRL0IJ	RXF 393	Investigative	[12]
Invasive ductal carcinoma	DC2V8MY	BT-549	Investigative	[12]
Invasive ductal carcinoma	DCHVSKR	HS 578T	Investigative	[12]
Adenocarcinoma	DCMQG9R	OVCAR3	Investigative	[1]
Adenocarcinoma	DCCW4JM	HT29	Investigative	[1]
Adenocarcinoma	DC438Y6	HCT116	Investigative	[1]
Adenocarcinoma	DCQZVT6	HCT-15	Investigative	[1]
Amelanotic melanoma	DCQULVA	MDA-MB-435	Investigative	[1]
Cutaneous melanoma	DCGXGNC	SK-MEL-28	Investigative	[1]
High grade ovarian serous adenocarcinoma	DCRQPXM	NCI\\/ADR-RES	Investigative	[1]
Lung adenocarcinoma	DCTX2L6	EKVX	Investigative	[1]
Melanoma	DCV5ADR	MALME-3M	Investigative	[1]
Melanoma	DC9YTCS	SK-MEL-2	Investigative	[1]
Minimally invasive lung adenocarcinoma	DCMKAIP	NCI-H322M	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 16 DrugCom(s)

References

1	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
2	Lenalidomide FDA Label
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7331).
4	Low-dose Lenalidomide for Non-severe COVID-19 Treatment Trial (GETAFE)
5	Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs. 2008 Mar;11(3):204-14.
6	Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351.
7	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB00480)
8	Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood. 2005 Apr 15;105(8):3286-94. doi: 10.1182/blood-2004-06-2101. Epub 2004 Dec 23.
9	Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat Struct Mol Biol. 2014 Sep;21(9):803-9. doi: 10.1038/nsmb.2874. Epub 2014 Aug 10.
10	Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. Elife. 2018 Aug 1;7:e38430. doi: 10.7554/eLife.38430.
11	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
12	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165